Pancreatic neuroendocrine tumors � Bridging knowledge gaps for better outcomes

Clinical decision-making in patients with pancreatic neuroendocrine tumors is complex. The absence of effective biomarkers and the reliance on morphological criteria underlying current predictive models expose patients to a substantial risk of overdiagnosis and overtreatment. The implementation of non-invasive tools that improve the precision of prognostic estimates remains an unmet clinical need.